title: Involvement of ADAM9 in multinucleated giant cell formation of blood monocytes.
abstract: Monocytes-macrophages are converted to multinucleated giant cells by stimulation with various cytokines, and osteoclasts are the multinucleated giant cells derived from a monocyte-macrophage lineage. However, at present, the fusion peptides have not been clearly identified in monocytes-macrophages. The ADAM are a family of transmembrane glycoproteins that have a role in various biological functions. Interestingly, fertilin-alpha, ADAM9, and ADAM11 have potential fusion peptides. In this study, which ADAM was specifically expressed in monocytes stimulated with anti-CD98 antibody or RANKL and which factor(s) was functioning in monocytes as a fusion protein were investigated. ADAM1, 8, 10, 12, 15, 17, 20, and 21 mRNAs are expressed in blood monocytes incubated with control antibody, anti-FRP-1/CD98 antibody, or RANKL + M-CSF, while ADAM2, 7, 11, 13, 19, 23, 29, and 30 mRNAs could not be detected in these blood monocytes. Expression of ADAM9 and ADAM10 mRNAs are enhanced by either RANKL + M-CSF or anti-CD98 antibody. The expression of ADAM9 and ADAM10 is also induced in blood monocytes by anti-CD98 mAb. An anti-ADAM9 antibody enhances CD98-mediated cell aggregation, while it blocks CD98-mediated and RANKL-mediated multinucleated giant cell formation. A hydroxamate-based metalloprotease inhibitor, SI-27, which is found to suppress ADAM9 activity, suppresses multinucleated giant cell formation. New protein synthesis is necessary for the expression of ADAM9 mRNA and genistein suppresses induction of ADAM9 mRNA. This is the first report that ADAM9 is involved in monocyte fusion, such as CD98-mediated and RANKL-mediated cell fusion of blood monocytes. Furthermore, AMAM9 is one candidate for a fusion peptide in blood monocytes.
authors.affiliation: Department of Microbiology, Mie University School of Medicine, 2-174, Edobashi, Tsu-Shi, Mie Prefecture, 514-8507, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Namba
authors.forename: M
authors.initials: M
authors.lastname: Nishio
authors.forename: K
authors.initials: K
authors.lastname: Mori
authors.forename: N
authors.initials: N
authors.lastname: Miyamoto
authors.forename: M
authors.initials: M
authors.lastname: Tsurudome
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: M
authors.initials: M
authors.lastname: Kawano
authors.forename: A
authors.initials: A
authors.lastname: Uchida
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
mesh_terms: D051722:ADAM Proteins; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D016227:Benzoquinones; D002352:Carrier Proteins / Q000276:immunology / Q000494:pharmacology; D002454:Cell Differentiation; D002459:Cell Fusion; D003513:Cycloheximide / Q000494:pharmacology; D019483:Disintegrins / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D027261:Fusion Regulatory Protein-1 / Q000276:immunology; D019833:Genistein / Q000494:pharmacology; D015726:Giant Cells / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D047029:Lactams, Macrocyclic; D016173:Macrophage Colony-Stimulating Factor / Q000276:immunology / Q000494:pharmacology; D061965:Matrix Metalloproteinase Inhibitors; D008562:Membrane Glycoproteins / Q000276:immunology / Q000494:pharmacology; D008565:Membrane Proteins; D008666:Metalloendopeptidases / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D009000:Monocytes / Q000166:cytology* / Q000187:drug effects / Q000276:immunology; D009842:Oligopeptides / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011809:Quinones / Q000494:pharmacology; D053245:RANK Ligand; D012333:RNA, Messenger / Q000096:biosynthesis; D053246:Receptor Activator of Nuclear Factor-kappa B; D017828:Rifabutin / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; D016227:Benzoquinones; D002352:Carrier Proteins; D019483:Disintegrins; D027261:Fusion Regulatory Protein-1; D006877:Hydroxamic Acids; D047029:Lactams, Macrocyclic; D061965:Matrix Metalloproteinase Inhibitors; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D009842:Oligopeptides; D011500:Protein Synthesis Inhibitors; D011809:Quinones; D053245:RANK Ligand; D012333:RNA, Messenger; D053246:Receptor Activator of Nuclear Factor-kappa B; C421267:SI 27; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human; D017828:Rifabutin; C020754:herbimycin; D016173:Macrophage Colony-Stimulating Factor; D003513:Cycloheximide; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D051722:ADAM Proteins; C098339:ADAM9 protein, human; D008666:Metalloendopeptidases